常染色体显性多囊肾病临床试验的终点选择
常染色体显性多囊肾病(ADPKD)进展缓慢且个体差异大,死亡或肾衰竭等临床终点发生少且晚,需长期随访和大样本。替代终点如GFR或肾脏体积变化在不同人群效度不一。本文探讨ADPKD结局选择困难的原因,分析现代试验设计如何减轻这些困难,并概述ADPKD试验常用结局。
要点
- ADPKD进展缓慢且个体差异大,临床终点需长期随访和大样本。
- 替代终点如GFR或肾脏体积变化在不同人群效度不一。
- 富集高危进展患者可缓解挑战但限制结果外推性。
核心结论
- ADPKD临床试验终点选择面临挑战,需考虑疾病进展缓慢和个体差异大的特点。
- 替代终点在不同ADPKD患者人群中效度不一,需谨慎选择。
- 富集高危患者和新型试验设计可能缓解终点选择困难,但各有局限。
研究设计与样本
- 本文为综述,探讨ADPKD临床试验终点选择的挑战、现代试验设计的应用及常用结局概述。
主要发现
- ADPKD进展缓慢且个体差异大,死亡或肾衰竭等临床终点发生少且晚。
- 使用临床终点需长期随访和大样本。
- 替代终点如GFR或肾脏体积变化在不同ADPKD患者人群中效度不一。
- 富集高危进展患者可缓解部分挑战,但限制结果外推性。
- 新型试验设计可能减轻部分终点选择问题。
临床怎么用
- 在ADPKD临床试验设计中,需根据疾病进展特点和人群差异选择合适终点。
- 可考虑富集高危患者或采用新型试验设计以缓解终点选择困难。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autosomal dominant polycystic kidney disease (ADPKD) is the leading hereditary cause of kidney failure. Challenges have arisen in developing consensus-based clinical trial end points endorsed by the wider ADPKD research community and regulators. Disease progression in ADPKD occurs slowly and is highly variable between patients. Clinical end points such as death or kidney failure occur infrequently and late in the condition. Thus, their use as outcomes in ADPKD trials requires prolonged follow-up and large sample sizes. Furthermore, because of the nature of ADPKD progression, surrogate outcomes such as change in glomerular filtration rate (GFR) or kidney volume, have varying validity in different populations of patients with ADPKD. Alternative trial approaches, such as enriching trial populations with patients at high risk of disease progression, have the potential to mitigate some of these challenges, although they limit the generalizability of results. The emergence of novel trial designs presents potential approaches to alleviate some of these issues. This paper explores some of the unique features of ADPKD from which difficulties in outcome selection arise, examines how modern trial designs can lessen some of these features, and provides an overview of commonly reported outcomes in ADPKD trials.
引用
- St Pierre K, El-Damanawi R, Jefferis J, et al. End Point Selection in ADPKD Clinical Trials. Kidney Int Rep. 2025. PMID: 41278330. doi:10.1016/j.ekir.2025.09.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。